Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Staphylococcus Aureus Infections-Pipeline Review, H1 2015

Staphylococcus Aureus Infections-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Staphylococcus Aureus Infections-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Staphylococcus Aureus Infections-Pipeline Review, H1 2015', provides an overview of the Staphylococcus Aureus Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Staphylococcus Aureus Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Staphylococcus Aureus Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Staphylococcus Aureus Infections

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Staphylococcus Aureus Infections and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Staphylococcus Aureus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Staphylococcus Aureus Infections pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Staphylococcus Aureus Infections

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Staphylococcus Aureus Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Staphylococcus Aureus Infections Overview 8

Therapeutics Development 9

Staphylococcus Aureus Infections-Therapeutics under Development by Companies 11

Staphylococcus Aureus Infections-Therapeutics under Investigation by Universities/Institutes 20

Staphylococcus Aureus Infections-Pipeline Products Glance 24

Staphylococcus Aureus Infections-Products under Development by Companies 28

Staphylococcus Aureus Infections-Products under Investigation by Universities/Institutes 41

Staphylococcus Aureus Infections-Companies Involved in Therapeutics Development 47

Staphylococcus Aureus Infections-Therapeutics Assessment 140

Drug Profiles 152

Staphylococcus Aureus Infections-Recent Pipeline Updates 416

Staphylococcus Aureus Infections-Dormant Projects 469

Staphylococcus Aureus Infections-Discontinued Products 482

Staphylococcus Aureus Infections-Product Development Milestones 484

Appendix 491

List of Tables

Number of Products under Development for Staphylococcus Aureus Infections, H1 2015 33

Number of Products under Development for Staphylococcus Aureus Infections-Comparative Analysis, H1 2015 34

Number of Products under Development by Companies, H1 2015 36

Number of Products under Development by Companies, H1 2015 (Contd..1) 37

Number of Products under Development by Companies, H1 2015 (Contd..2) 38

Number of Products under Development by Companies, H1 2015 (Contd..3) 39

Number of Products under Development by Companies, H1 2015 (Contd..4) 40

Number of Products under Development by Companies, H1 2015 (Contd..5) 41

Number of Products under Development by Companies, H1 2015 (Contd..6) 42

Number of Products under Development by Companies, H1 2015 (Contd..7) 43

Number of Products under Investigation by Universities/Institutes, H1 2015 45

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 46

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 47

Comparative Analysis by Late Stage Development, H1 2015 48

Comparative Analysis by Clinical Stage Development, H1 2015 49

Comparative Analysis by Early Stage Development, H1 2015 50

Comparative Analysis by Unknown Stage Development, H1 2015 51

Products under Development by Companies, H1 2015 52

Products under Development by Companies, H1 2015 (Contd..1) 53

Products under Development by Companies, H1 2015 (Contd..2) 54

Products under Development by Companies, H1 2015 (Contd..3) 55

Products under Development by Companies, H1 2015 (Contd..4) 56

Products under Development by Companies, H1 2015 (Contd..5) 57

Products under Development by Companies, H1 2015 (Contd..6) 58

Products under Development by Companies, H1 2015 (Contd..7) 59

Products under Development by Companies, H1 2015 (Contd..8) 60

Products under Development by Companies, H1 2015 (Contd..9) 61

Products under Development by Companies, H1 2015 (Contd..10) 62

Products under Development by Companies, H1 2015 (Contd..11) 63

Products under Development by Companies, H1 2015 (Contd..12) 64

Products under Investigation by Universities/Institutes, H1 2015 65

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 66

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 67

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 68

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 69

Products under Investigation by Universities/Institutes, H1 2015 (Contd..5) 70

Staphylococcus Aureus Infections-Pipeline by Absynth Biologics Limited, H1 2015 71

Staphylococcus Aureus Infections-Pipeline by Actelion Ltd, H1 2015 72

Staphylococcus Aureus Infections-Pipeline by Adenium Biotech ApS, H1 2015 73

Staphylococcus Aureus Infections-Pipeline by AIMM Therapeutics B.V., H1 2015 74

Staphylococcus Aureus Infections-Pipeline by Alchemia Limited, H1 2015 75

Staphylococcus Aureus Infections-Pipeline by Allergan Plc, H1 2015 76

Staphylococcus Aureus Infections-Pipeline by AlphaMab Co., Ltd, H1 2015 77

Staphylococcus Aureus Infections-Pipeline by Alvogen, Inc., H1 2015 78

Staphylococcus Aureus Infections-Pipeline by AmpliPhi Biosciences Corporation, H1 2015 79

Staphylococcus Aureus Infections-Pipeline by AnGes MG, Inc., H1 2015 80

Staphylococcus Aureus Infections-Pipeline by Aphios Corporation, H1 2015 81

Staphylococcus Aureus Infections-Pipeline by Arsanis Biosciences GmbH, H1 2015 82

Staphylococcus Aureus Infections-Pipeline by AstraZeneca Plc, H1 2015 83

Staphylococcus Aureus Infections-Pipeline by Aureogen Biosciences, Inc., H1 2015 84

Staphylococcus Aureus Infections-Pipeline by Aurigene Discovery Technologies Limited, H1 2015 85

Staphylococcus Aureus Infections-Pipeline by Bharat Biotech International Limited, H1 2015 86

Staphylococcus Aureus Infections-Pipeline by BioDiem Ltd, H1 2015 87

Staphylococcus Aureus Infections-Pipeline by Biomar Microbial Technologies, H1 2015 88

Staphylococcus Aureus Infections-Pipeline by C3 Jian, Inc, H1 2015 89

Staphylococcus Aureus Infections-Pipeline by Cellceutix Corporation, H1 2015 90

Staphylococcus Aureus Infections-Pipeline by Cempra, Inc., H1 2015 91

Staphylococcus Aureus Infections-Pipeline by ContraFect Corporation, H1 2015 92

Staphylococcus Aureus Infections-Pipeline by CrystalGenomics, Inc., H1 2015 93

Staphylococcus Aureus Infections-Pipeline by CSA Biotechnologies LLC , H1 2015 94

Staphylococcus Aureus Infections-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 95

Staphylococcus Aureus Infections-Pipeline by Debiopharm International S.A., H1 2015 96

Staphylococcus Aureus Infections-Pipeline by DesignMedix, Inc., H1 2015 97

Staphylococcus Aureus Infections-Pipeline by Destiny Pharma Limited, H1 2015 98

Staphylococcus Aureus Infections-Pipeline by Dong-A Socio Group, H1 2015 99

Staphylococcus Aureus Infections-Pipeline by Ensoltek Co., Ltd., H1 2015 100

Staphylococcus Aureus Infections-Pipeline by Excelimmune, Inc., H1 2015 101

Staphylococcus Aureus Infections-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 102

Staphylococcus Aureus Infections-Pipeline by Galapagos NV, H1 2015 103

Staphylococcus Aureus Infections-Pipeline by GangaGen Inc., H1 2015 104

Staphylococcus Aureus Infections-Pipeline by Genentech, Inc., H1 2015 105

Staphylococcus Aureus Infections-Pipeline by GlaxoSmithKline Plc, H1 2015 106

Staphylococcus Aureus Infections-Pipeline by GlycoVaxyn AG, H1 2015 107

Staphylococcus Aureus Infections-Pipeline by Helix BioMedix, Inc., H1 2015 108

Staphylococcus Aureus Infections-Pipeline by Humabs BioMed SA, H1 2015 109

Staphylococcus Aureus Infections-Pipeline by Ildong Pharmaceutical Co., Ltd., H1 2015 110

Staphylococcus Aureus Infections-Pipeline by Imaxio SA, H1 2015 111

Staphylococcus Aureus Infections-Pipeline by Immupharma Plc, H1 2015 112

Staphylococcus Aureus Infections-Pipeline by ImmuVen, Inc., H1 2015 113

Staphylococcus Aureus Infections-Pipeline by Integrated BioTherapeutics, Inc., H1 2015 114

Staphylococcus Aureus Infections-Pipeline by iNtRON Biotechnology Inc., H1 2015 115

Staphylococcus Aureus Infections-Pipeline by Kyorin Pharmaceutical Co., Ltd., H1 2015 116

Staphylococcus Aureus Infections-Pipeline by Lascco SA, H1 2015 117

Staphylococcus Aureus Infections-Pipeline by LegoChem Biosciences, Inc, H1 2015 118

Staphylococcus Aureus Infections-Pipeline by Lytix Biopharma AS, H1 2015 119

Staphylococcus Aureus Infections-Pipeline by Madam Therapeutics B.V., H1 2015 120

Staphylococcus Aureus Infections-Pipeline by Melinta Therapeutics, Inc, H1 2015 121

Staphylococcus Aureus Infections-Pipeline by Merck & Co., Inc., H1 2015 122

Staphylococcus Aureus Infections-Pipeline by MGB Biopharma Limited, H1 2015 123

Staphylococcus Aureus Infections-Pipeline by Microbiotix, Inc., H1 2015 124

Staphylococcus Aureus Infections-Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015 125

Staphylococcus Aureus Infections-Pipeline by MorphoSys AG, H1 2015 126

Staphylococcus Aureus Infections-Pipeline by Morphotek, Inc., H1 2015 127

Staphylococcus Aureus Infections-Pipeline by Motif BioSciences, Inc., H1 2015 128

Staphylococcus Aureus Infections-Pipeline by Nabriva Therapeutics AG, H1 2015 129

Staphylococcus Aureus Infections-Pipeline by NanoBio Corporation, H1 2015 130

Staphylococcus Aureus Infections-Pipeline by NovaBay Pharmaceuticals, Inc., H1 2015 131

Staphylococcus Aureus Infections-Pipeline by Novabiotics Limited, H1 2015 132

Staphylococcus Aureus Infections-Pipeline by NovaDigm Therapeutics, Inc., H1 2015 133

Staphylococcus Aureus Infections-Pipeline by Novan, Inc., H1 2015 134

Staphylococcus Aureus Infections-Pipeline by NovoBiotic Pharmaceuticals, LLC, H1 2015 135

Staphylococcus Aureus Infections-Pipeline by Novolytics Limited, H1 2015 136

Staphylococcus Aureus Infections-Pipeline by Omnia Molecular Ltd., H1 2015 137

Staphylococcus Aureus Infections-Pipeline by Oragenics, Inc., H1 2015 138

Staphylococcus Aureus Infections-Pipeline by Pepscan Presto BV, H1 2015 139

Staphylococcus Aureus Infections-Pipeline by Pfizer Inc., H1 2015 140

Staphylococcus Aureus Infections-Pipeline by PharmaIN Corporation, H1 2015 141

Staphylococcus Aureus Infections-Pipeline by Phico Therapeutics Limited, H1 2015 142

Staphylococcus Aureus Infections-Pipeline by Phylogica Limited, H1 2015 143

Staphylococcus Aureus Infections-Pipeline by Pono Pharma, H1 2015 144

Staphylococcus Aureus Infections-Pipeline by Procarta Biosystems Ltd, H1 2015 145

Staphylococcus Aureus Infections-Pipeline by Redx Pharma Plc, H1 2015 146

Staphylococcus Aureus Infections-Pipeline by Sarepta Therapeutics, Inc., H1 2015 147

Staphylococcus Aureus Infections-Pipeline by Savara Inc., H1 2015 148

Staphylococcus Aureus Infections-Pipeline by Sealife PHARMA GMBH, H1 2015 149

Staphylococcus Aureus Infections-Pipeline by Sentinella Pharmaceuticals, Inc., H1 2015 150

Staphylococcus Aureus Infections-Pipeline by Soligenix, Inc., H1 2015 151

Staphylococcus Aureus Infections-Pipeline by Sorrento Therapeutics, Inc., H1 2015 152

Staphylococcus Aureus Infections-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 153

Staphylococcus Aureus Infections-Pipeline by Syntiron LLC, H1 2015 154

Staphylococcus Aureus Infections-Pipeline by Taejoon Pharm Co., Ltd., H1 2015 155

Staphylococcus Aureus Infections-Pipeline by TAXIS Pharmaceuticals, Inc., H1 2015 156

Staphylococcus Aureus Infections-Pipeline by Techulon, Inc., H1 2015 157

Staphylococcus Aureus Infections-Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015 158

Staphylococcus Aureus Infections-Pipeline by United Therapeutics Corporation, H1 2015 159

Staphylococcus Aureus Infections-Pipeline by Wintermute Biomedical LLC, H1 2015 160

Staphylococcus Aureus Infections-Pipeline by Wockhardt Limited, H1 2015 161

Staphylococcus Aureus Infections-Pipeline by XBiotech USA, Inc., H1 2015 162

Staphylococcus Aureus Infections-Pipeline by Yungjin Pharm Ind. Co., Ltd., H1 2015 163

Assessment by Monotherapy Products, H1 2015 164

Assessment by Combination Products, H1 2015 165

Number of Products by Stage and Target, H1 2015 167

Number of Products by Stage and Mechanism of Action, H1 2015 170

Number of Products by Stage and Route of Administration, H1 2015 173

Number of Products by Stage and Molecule Type, H1 2015 175

Staphylococcus Aureus Infections Therapeutics-Recent Pipeline Updates, H1 2015 440

Staphylococcus Aureus Infections-Dormant Projects, H1 2015 493

Staphylococcus Aureus Infections-Dormant Projects (Contd..1), H1 2015 494

Staphylococcus Aureus Infections-Dormant Projects (Contd..2), H1 2015 495

Staphylococcus Aureus Infections-Dormant Projects (Contd..3), H1 2015 496

Staphylococcus Aureus Infections-Dormant Projects (Contd..4), H1 2015 497

Staphylococcus Aureus Infections-Dormant Projects (Contd..5), H1 2015 498

Staphylococcus Aureus Infections-Dormant Projects (Contd..6), H1 2015 499

Staphylococcus Aureus Infections-Dormant Projects (Contd..7), H1 2015 500

Staphylococcus Aureus Infections-Dormant Projects (Contd..8), H1 2015 501

Staphylococcus Aureus Infections-Dormant Projects (Contd..9), H1 2015 502

Staphylococcus Aureus Infections-Dormant Projects (Contd..10), H1 2015 503

Staphylococcus Aureus Infections-Dormant Projects (Contd..11), H1 2015 504

Staphylococcus Aureus Infections-Dormant Projects (Contd..12), H1 2015 505

Staphylococcus Aureus Infections-Discontinued Products, H1 2015 506

Staphylococcus Aureus Infections-Discontinued Products (Contd..1), H1 2015 507

List of Figures

Number of Products under Development for Staphylococcus Aureus Infections, H1 2015 33

Number of Products under Development for Staphylococcus Aureus Infections-Comparative Analysis, H1 2015 34

Number of Products under Development by Companies, H1 2015 35

Number of Products under Investigation by Universities/Institutes, H1 2015 44

Comparative Analysis by Clinical Stage Development, H1 2015 49

Comparative Analysis by Early Stage Products, H1 2015 50

Assessment by Monotherapy Products, H1 2015 164

Number of Products by Top 10 Targets, H1 2015 166

Number of Products by Stage and Top 10 Targets, H1 2015 166

Number of Products by Top 10 Mechanism of Actions, H1 2015 169

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 169

Number of Products by Top 10 Routes of Administration, H1 2015 172

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 172

Number of Products by Top 10 Molecule Types, H1 2015 174

Number of Products by Stage and Top 10 Molecule Types, H1 2015 174

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Absynth Biologics Limited

Actelion Ltd

Adenium Biotech ApS

AIMM Therapeutics B.V.

Alchemia Limited

Allergan Plc

AlphaMab Co., Ltd

Alvogen, Inc.

AmpliPhi Biosciences Corporation

AnGes MG, Inc.

Aphios Corporation

Arsanis Biosciences GmbH

AstraZeneca Plc

Aureogen Biosciences, Inc.

Aurigene Discovery Technologies Limited

Bharat Biotech International Limited

BioDiem Ltd

Biomar Microbial Technologies

C3 Jian, Inc

Cellceutix Corporation

Cempra, Inc.

ContraFect Corporation

CrystalGenomics, Inc.

CSA Biotechnologies LLC

Daiichi Sankyo Company, Limited

Debiopharm International S.A.

DesignMedix, Inc.

Destiny Pharma Limited

Dong-A Socio Group

Ensoltek Co., Ltd.

Excelimmune, Inc.

F. Hoffmann-La Roche Ltd.

Galapagos NV

GangaGen Inc.

Genentech, Inc.

GlaxoSmithKline Plc

GlycoVaxyn AG

Helix BioMedix, Inc.

Humabs BioMed SA

Ildong Pharmaceutical Co., Ltd.

Imaxio SA

Immupharma Plc

ImmuVen, Inc.

Integrated BioTherapeutics, Inc.

iNtRON Biotechnology Inc.

Kyorin Pharmaceutical Co., Ltd.

Lascco SA

LegoChem Biosciences, Inc

Lytix Biopharma AS

Madam Therapeutics B.V.

Melinta Therapeutics, Inc

Merck & Co., Inc.

MGB Biopharma Limited

Microbiotix, Inc.

MicuRx Pharmaceuticals, Inc.

MorphoSys AG

Morphotek, Inc.

Motif BioSciences, Inc.

Nabriva Therapeutics AG

NanoBio Corporation

NovaBay Pharmaceuticals, Inc.

Novabiotics Limited

NovaDigm Therapeutics, Inc.

Novan, Inc.

NovoBiotic Pharmaceuticals, LLC

Novolytics Limited

Omnia Molecular Ltd.

Oragenics, Inc.

Pepscan Presto BV

Pfizer Inc.

PharmaIN Corporation

Phico Therapeutics Limited

Phylogica Limited

Pono Pharma

Procarta Biosystems Ltd

Redx Pharma Plc

Sarepta Therapeutics, Inc.

Savara Inc.

Sealife PHARMA GMBH

Sentinella Pharmaceuticals, Inc.

Soligenix, Inc.

Sorrento Therapeutics, Inc.

Sumitomo Dainippon Pharma Co., Ltd.

Syntiron LLC

Taejoon Pharm Co., Ltd.

TAXIS Pharmaceuticals, Inc.

Techulon, Inc.

Tetraphase Pharmaceuticals Inc.

United Therapeutics Corporation

Wintermute Biomedical LLC

Wockhardt Limited

XBiotech USA, Inc.

Yungjin Pharm Ind. Co., Ltd.

Staphylococcus Aureus Infections Therapeutic Products under Development, Key Players in Staphylococcus Aureus Infections Therapeutics, Staphylococcus Aureus Infections Pipeline Overview, Staphylococcus Aureus Infections Pipeline, Staphylococcus Aureus Infections Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com